Jazz Pharmaceuticals plc
Research Jazz Pharmaceuticals plc (JAZZ) on Bullrun: market cap USD 16.86B, P/E 17.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJAZZ
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 16.86B
- P/E17.9
- Financial periodQ2 2026
- RevenueUSD 1.21B
- Net incomeUSD 192.80M
- Free cash flowUSD 243.40M
- Gross margin90.4%
Valuation Snapshot
latest market cap is USD 16.86B; P/E is 17.9.
Peer valuation comparison
Latest P/E is 17.95x versus a Healthcare sector median of 24.46x (26.6% below).
Latest P/E is 17.95x versus a Ireland median of 22.15x (19.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.27B | -USD 356.15M | USD 1.30B | 88.2% | -5.84 | USD 1.39B | USD 5.36B | USD 4.32B |
| FY2024 | USD 4.07B | USD 560.12M | USD 1.36B | 89.0% | 8.65 | USD 2.41B | USD 6.11B | USD 4.09B |
| FY2023 | USD 3.83B | USD 414.83M | USD 1.07B | n/a | 6.1 | USD 1.51B | USD 5.71B | USD 3.74B |
| FY2022 | USD 3.66B | -USD 224.06M | USD 1.24B | n/a | -3.58 | USD 881.48M | USD 5.72B | USD 3.09B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 16.86B | 17.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.44B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 7.47B | 14.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.74B | 205.0 | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.03B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.85B | n/a | n/a | n/a |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jazz Pharmaceuticals plc's market cap?
Jazz Pharmaceuticals plc's market capitalization is USD 16.86B.
What is Jazz Pharmaceuticals plc's P/E ratio?
Jazz Pharmaceuticals plc's price-to-earnings (P/E) ratio is 17.9.
What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.